AYTU BIOPHARMA, INC. Lead Drug Candidate Success Prediction
Resolves: The company announces successful completion of Phase 3 clinical trials for its lead drug candidate.
sec_filing· CLINICAL
AYTU BIOPHARMA, INC. Lead Drug Candidate Success Prediction
Market overview
Derived from AYTU BIOPHARMA, INC (AYTU) (CIK 0001385818) 10-Q filing analysis
CLINICAL prediction market
- Implied probability (Yes)
- 55%
- Closes
- 2027-06-30
About this prediction
Resolution criteria
The company announces successful completion of Phase 3 clinical trials for its lead drug candidate.
No one's made a Conviction call on this yet. Be the first to call it →
Loading…